FDA Drug Recalls

Recalls / Class II

Class IID-0361-2022

Product

Pregabalin Capsules, 50 mg, 100 count bottle, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd., Survey No. 259/15 Dadra-396 191, (U.T. of D & NH), India, NDC 47335-687-88.

Brand name
Pregabalin
Generic name
Pregabalin
Active ingredient
Pregabalin
Route
Oral
NDCs
47335-686, 47335-687, 47335-688, 47335-689, 47335-690, 47335-691, 47335-692, 47335-693
FDA application
ANDA091157
Affected lot / code info
Lot number: DNC0432A, expiration 01/2023

Why it was recalled

Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient.

Recalling firm

Firm
SUN PHARMACEUTICAL INDUSTRIES INC
Manufacturer
Sun Pharmaceutical Industries, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
2 Independence Way, N/A, Princeton, New Jersey 08540-6620

Distribution

Quantity
696 Bottles
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2021-10-22
FDA classified
2022-01-06
Posted by FDA
2022-01-12
Terminated
2023-04-06
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0361-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Pregabalin · FDA Drug Recalls